Treatment of age-related decline in mental capacity, primary progressive dementia, alzheimer dementia, multi-infarct dementia and senile onset.
How it works
Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.
Common side effects
Vomiting, Gastrointestinal disorder, Lightheadedness, Loss of appetite, Running nose, Nasal congestion, Stomach upset, Tongue ulcer, Warm sensation
- 1 variant(s)